Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v14-FR Version v7-EN
Language French English
Date Updated 2024-10-15 2024-09-21
Drug Identification Number 02362597 02362597
Brand name POTASSIUM ACETATE INJECTION USP POTASSIUM ACETATE INJECTION USP
Common or Proper name POTASSIUM ACETATE INJECTION POTASSIUM ACETATE INJECTION
Company Name OMEGA LABORATORIES LIMITED OMEGA LABORATORIES LIMITED
Ingredients POTASSIUM ACETATE POTASSIUM ACETATE
Strength(s) 39.2% 39.2%
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 10 x 50mL vial / fiole 10 x 50mL vial / fiole
ATC code B05XA B05XA
ATC description I.V. SOLUTION ADDITIVES I.V. SOLUTION ADDITIVES
Reason for shortage Shortage of an active ingredient. Shortage of an active ingredient.
Anticipated start date 2024-09-13 2024-09-13
Actual start date 2024-09-20 2024-09-20
Estimated end date 2024-10-23 2025-01-06
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Sodium Acetate, which can be used as a substitute for Potassium Acetate, is also available at CPDN and Omega. The product remains available at CPDN Delta and Omega. Sodium Acetate, which can be used as a substitute for Potassium Acetate, is also available at CPDN and Omega.
Health Canada comments